Candida famata central nervous system infection [1]

South African Medical Journal

Volumn 93, Issue 8, 2003, Pages 601-602

  Prinsloo, B ^a   Weldhagen, G F ^a   Blaine, R W ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CEFOTAXIME; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIAL MENINGITIS; CANDIDA; CANDIDA FAMATA; CANDIDIASIS; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HEADACHE; HUMAN; LETTER; LUMBAR PUNCTURE; MALE; VOMITING;

ADULT; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTIONS; FATAL OUTCOME; HUMANS; MALE;

EID: 0042825554     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995; 8: 462-478.
2. Gripshover B, Ellner JJ. Chronic meningitis. In: Mandell GL, ed. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingstone, 1999.
3. Krcmery V, Kunova A. Candida famata fungemia in a cancer patient: case report. J Chemother 2000; 12: 189-190.
4. Carrega G, Riccio G, Santoriello L, Pasqualini M, Pellicci R. Candida famata fungemia in a surgical patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16: 698-699.
5. Quindos G, Cabrera F, Arilla MC, et al. Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole. Clin Infect Dis 1994; 18: 658-660.
6. Gray LD, Fedorko DP. Laboratory diagnosis of bacterial meningitis. Clin Microbiol Rev 1992; 5: 130-145.
7. Michel-Nguyen A, Favel A, Chastin C, Selva M, Regli P. Comparative evaluation of a commercial system for identification of Candida lusitaniae. Eur J Clin Microbiol Infect Dis 2000; 19: 393-395.
8. Barchiesi F, Tortorano AM, Di Francesco LF, Cogliati M, Scalise G, Viviani MA. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother 1999; 43: 295-299.
9. Khan ZU, Mizra VC, Rhandhawa HS, Damodaran VN. Pathogenicity of some ordinarily harmless yeasts for cortisone-treated mice. Sabouraudia 1980; 18: 319-327.